PLP 33
Alternative Names: PLP-33Latest Information Update: 31 Mar 2022
At a glance
- Originator Cannabics Pharmaceuticals
- Developer CNBX Pharmaceuticals
- Class Antineoplastics; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Intestinal polyps
Most Recent Events
- 28 Mar 2022 Cannabics Pharmaceuticals is now called CNBX Pharmaceuticals
- 07 Oct 2021 Cannabics Pharmaceuticals plans for submission of pre-IND meeting request with US FDA (Cannabics Pharmaceuticals pipeline)
- 01 Oct 2021 Preclinical trials in Intestinal polyps in USA (unspecified route) (Cannabics Pharmaceuticals pipeline)